PATENT CLAIM ANALYSIS

Application Number: 16029239
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "452000"]

Abstract:
The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 μg/kg body weight/minute and 20 μg/kg body weight/minute.

Claim (Index 2):
The oral controlled-release formulation of  claim 1 , wherein the at least one adverse event is a statistically significant increase in the rate of mortality, morbidity, angina, blurred vision, dizziness, hypotension, palpitations, syncope, arrhythmias, heart rate, diarrhea, or headache.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 95.0
- Lexical Diversity: 1.6383
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14238961', '15538123', '10453848', '10269551', '12755847']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7253039584245268
- 35 USC 102 Novelty (BERT): 0.5937423588653818
- Combined Prediction Score: 0.7121477984686123
- Mean Citation Score: 327.600582
- Max Citation Score: 599.7304
- Similarity Product: 409.9600852148056

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test